FAQ
An IND readiness assessment is a structured pre-submission review that helps biotech and pharma teams evaluate nonclinical readiness, CMC readiness, clinical protocol design, starting-dose rationale, and clinical hold risk signals before filing an Investigational New Drug application with the FDA. It supports expert review and is not a replacement for regulatory advice.
Common questions about IND readiness assessments, FDA submission risk review, pre-IND meeting preparation, nonclinical IND-enabling studies, CMC readiness, and clinical hold risk signals.
An IND readiness assessment helps evaluate whether an IND package is complete and whether the regulatory argument is strong. It looks across nonclinical, CMC, clinical protocol, starting-dose, and safety dimensions to identify potential FDA question areas and clinical hold risk indicators before submission.
Biotech founders, pharma regulatory affairs teams, preclinical and translational teams, clinical development teams, regulatory consultants preparing INDs, and investors evaluating IND-stage programs.
No. This site connects teams to Alenvo's AI-assisted regulatory readiness workflows. The output is decision-support that helps structure expert review. It is not a replacement for regulatory, legal, clinical, or investment advice.
No. The intake form is for an initial conversation. Share only what is appropriate at that stage. Detailed package review is handled separately under appropriate confidentiality terms.
indreadinessassessment.com is a focused product entry point for Alenvo's AI-assisted regulatory, diligence, and evidence evaluation workflows. Requests submitted here are routed to the Alenvo team.
No. The assessment supports expert review and helps structure evaluation, identify potential gaps, and prioritize diligence questions. It is not legal, medical, regulatory, clinical, or investment advice.
Request an IND readiness assessment connected to Alenvo.
Check IND Readiness